Investors will be hoping for strength from CRON as it approaches its next earnings release. The company is expected to report EPS of -$0.03, unchanged from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $10.44 million, up 262.57% from the prior-year quarter.

Puration  (PURA OTC) Executes Its Business Model to Perfection

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.07 per share and revenue of $41.44 million. These totals would mark changes of +12.5% and +243.07%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for CRON. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Shorts Scramble On Goldman Research Report ALYI 

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRON is currently a Zacks Rank #3 (Hold).

The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 30% of all 250+ industries.